Evidence map›Paper›PMID 40042548›Full record

ArticleCancer immunology, immunotherapy : CII2025

LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8

Xiaoming Zhang, Hao Fang, Wenliang Wu, Congqing Jiang, Haizhou Wang, Yifei Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoming Zhang *Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Hao Fang *Department of Gastroenterology, Ningbo No.2 Hospital, Ningbo, 315010, China.
Wenliang Wu *Division of Gastrointestinal Surgery, Department of Surgery, Wuhan No.1 Hospital, Wuhan, 430022, China.
Congqing JiangDepartment of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. wb002554@whu.edu.cn.
Haizhou WangDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. 2016203030002@whu.edu.cn.
Yifei ShiDepartment of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. 11918416@zju.edu.cn.

Funding

National Natural Science Foundation of China 82303181
6 · The paper itself

Abstract

LPIN3 has emerged as a key factor in a variety of malignancies, although its precise role in colorectal cancer (CRC) remains unclear. By analyzing the data from The Cancer Genome Atlas, we discovered that the expression pattern of LPIN3 and the relevant makeup of the immune microenvironment were immensely diverse among tumors. LPIN3 is abundantly expressed in CRC and may enhance tumor growth by activating the β-catenin signaling pathway. In addition, we discovered that LPIN3 might reduce tumor antigen presentation signals, hence suppressing CD8

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsPhosphatidate PhosphataseAnimalsAntigen PresentationAntigens, NeoplasmApoptosisbeta CateninCell LineDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CSignal TransductionAntigens, Neoplasmbeta Cateninlipin 3 protein, mouseLPIN3 protein, humanPhosphatidate PhosphataseColorectal cancerImmune evasionImmunotherapyLPIN3

Identifiers

PMID40042548
PMCPMC11883066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.